UPADACITINIB
upadacitinib 30 mg modified release tablet, 28
UPADACITINIB (15382N)
15382N
Manner of administration:Oral
Restriction
Indication: Severe Crohn disease
Treatment phase: Initial 1 (induction treatment covering the first 12 weeks in a patient untreated
with targeted therapy)
Restriction
Indication: Severe Crohn disease
Treatment phase: Initial 2 (change or recommencement of treatment after a break in targeted therapy
of less than 12 months)
Restriction
Indication: Severe Crohn disease
Treatment phase: Initial 3 (recommencement of treatment after a break in targeted therapy of more than
12 months)
Restriction
Indication: Severe Crohn disease
Treatment phase: Balance of supply
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 28 | # of repeats: 2 | DPMQ: $1,983.58 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Rinvoq | |||||